DCVC and Magnetic Ventures, venture capital firms, led a $25m seed funding in Relation Therapeutics, a drug discovery company, with participation from Khosla Ventures, OMERS Ventures, Firstminute Capital, Peer Schatz, the former CEO of Qiagen, Jonathan Milner, founder of Abcam, and Mark Stevenson, former COO of ThermoFisher. “We will dramatically improve success in drug discovery—we must, because patients are waiting for breakthrough medicines. Our approach brings together, for the first time, human genetics, single-cell omics, functional genomics, and active-graph machine learning in a single, engineered design. We believe our techniques will significantly accelerate the discovery of new, life-changing drugs,” David Roblin, Relation Therapeutics CEO.